Stroke with hereditary cerebral small vessel diseases is a rare disease. Its clinical manifestations include early-onset ischemic lacunar or hemorrhagic stroke with high disability. Its typical imaging markers include lacunes, white matter hyperintensities, microbleeds, intracerebral hemorrhages located in deep or lobe of brain, crotical microinfarcts, and enlarged perivascular spaces. As the clinical and neuroimaging signs and symptoms of hereditary cerebral small vessel diseases often overlap with sporadic cerebral small vessel diseases, it is hard to diagnose. This article summarizes the clinical features, importance of obtaining valuable family history, genetic diagnosis, and management of stroke with hereditary cerebral small vessel disease to improve its accuracy diagnosis.
Objectives To analyze evidence-based medicine (EBM) related projects funded by National Natural Science Foundation of China (NSFC) from 2000 to 2019. Methods The online NSFC database, Internet-based Science Information System, Biomart.cn, and MedSci.com were searched to obtain all EBM grants funded by NSFC. The achievements, Chinese papers and SCI-indexed papers, were obtained by searching the database of CNKI, VIP, SinoMed, WanFang Data and Web of Science. All data screened and extracted manually, and then managed and analyzed with Microsoft Excel 2016 software. Results The NSFC has funded 94 projects regarding EBM, with a total amount of 44.763 million Yuan (RMB) since 2000. Beijing, Shanghai, Guangdong and Sichuan ranked highly in the number of projects and their undertaking institutions and total amount of fundings. General programs and youth scientist programs constituted the main parts of fundings. The funded projects mainly originated from three subjects of new technologies and methods of TCM, health management and policy, clinical basis of integrated Chinese and western medicine. General programs contributed the most articles, while the distinguished young scientist programs had the highest average outputs. Three papers from Chinese EBM Center were published on BMJ and were highly cited. Conclusions Support of NSFC on EBM has increased continuously for the last twenty years, but it is still below the average. The fundings are unbalanced in areas and institutions. The supported research fields change every year, and show a trend of subjects aggregation.
Patients with coronavirus disease 2019 may have systemic symptoms of varying degrees. These symptoms are related to inflammatory response, massive release of pro-inflammatory cytokines and cytokine storm. In recent years, programmed necrosis, as a controllable type of necrosis, is considered to be an important factor that mediates inflammation. Recent studies have shown that programmed necrosis is involved in the inflammatory response and pulmonary fibrosis of coronavirus disease 2019. This article mainly reviews the mechanism of programmed necrosis, its participation in the occurrence and development of coronavirus disease 2019, and the research progress of programmed necrosis inhibitors in the treatment of coronavirus disease 2019, aiming to provide a certain basis for the diagnosis and treatment of coronavirus disease 2019.